ATE293883T1 - Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen - Google Patents

Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen

Info

Publication number
ATE293883T1
ATE293883T1 AT97901425T AT97901425T ATE293883T1 AT E293883 T1 ATE293883 T1 AT E293883T1 AT 97901425 T AT97901425 T AT 97901425T AT 97901425 T AT97901425 T AT 97901425T AT E293883 T1 ATE293883 T1 AT E293883T1
Authority
AT
Austria
Prior art keywords
antioxidants
liver disease
cholestatic liver
treat cholestatic
treat
Prior art date
Application number
AT97901425T
Other languages
English (en)
Inventor
Ronald J Sokol
Original Assignee
Ronald J Sokol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ronald J Sokol filed Critical Ronald J Sokol
Application granted granted Critical
Publication of ATE293883T1 publication Critical patent/ATE293883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97901425T 1996-01-16 1997-01-15 Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen ATE293883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1004996P 1996-01-16 1996-01-16
PCT/US1997/000403 WO1997025864A1 (en) 1996-01-16 1997-01-15 Use of antioxidant agents to treat cholestatic liver disease

Publications (1)

Publication Number Publication Date
ATE293883T1 true ATE293883T1 (de) 2005-05-15

Family

ID=21743557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901425T ATE293883T1 (de) 1996-01-16 1997-01-15 Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen

Country Status (7)

Country Link
US (1) US6069167A (de)
EP (1) EP0893949B1 (de)
AT (1) ATE293883T1 (de)
AU (1) AU724620B2 (de)
CA (1) CA2242991C (de)
DE (1) DE69733132D1 (de)
WO (1) WO1997025864A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US6623734B2 (en) 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
US6855733B2 (en) * 2001-01-24 2005-02-15 Soft Gel Technologies, Inc. Formulation and manufacturing process for coenzyme Q10 soft gel capsules
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
WO2005032278A1 (en) 2003-09-29 2005-04-14 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US20050074445A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Alpha-tocopherol treatment for cystic fibrosis
US20050107465A1 (en) * 2003-10-01 2005-05-19 Papas Andreas M. Composition for treating inflammatory bowel disease
TW200524579A (en) * 2003-11-28 2005-08-01 Kaneka Corp Composition for protecting liver functions
US7790190B2 (en) * 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7284385B2 (en) * 2004-09-16 2007-10-23 Hess Spencer W Pre-dried air reactivation for diesel fuel heated dessicant reactivator
DE102004049339A1 (de) * 2004-10-08 2006-04-13 Basf Ag Verfahren zur Reinigung von phosphorhaltigen Chelat-Liganden
WO2006092449A2 (en) * 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
ATE539089T1 (de) * 2007-03-21 2012-01-15 Raptor Pharmaceutical Inc Cyclische rezeptor-assoziierte-proteine (rap)- peptide
US8197861B2 (en) * 2008-10-02 2012-06-12 George Zabrecky Methods and formulations for treating chronic liver disease
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) * 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (de) 2014-10-24 2016-04-27 Ferring BV Kristalline Form von elobixibat
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CA3011595C (en) 2016-02-09 2024-01-02 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP7665621B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158195A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh) 2021-06-03 2024-01-16 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125252A1 (de) * 1982-11-16 1984-11-21 MOTSCHAN, Georges Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine
DE69122099T2 (de) * 1990-05-16 1997-04-17 Margaret Hanausek Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
EP0746202A4 (de) * 1992-01-06 1997-06-25 Health Maintenance Programs Pharmazeutisch aktive antioxidant enthaltende zusammensetzung und verfahren zu ihrer verwendung in der vorbeugung und behandlung vom restenosis nach angioplastie
CN1080855A (zh) * 1993-05-22 1994-01-19 黎均耀 维生素矿物质防癌复方
DE4322070A1 (de) * 1993-07-02 1995-01-12 Ploch Eva Marina Umweltkapsel

Also Published As

Publication number Publication date
US6069167A (en) 2000-05-30
WO1997025864A1 (en) 1997-07-24
EP0893949A1 (de) 1999-02-03
CA2242991A1 (en) 1997-07-24
EP0893949A4 (de) 2002-01-02
CA2242991C (en) 2007-07-24
AU1532997A (en) 1997-08-11
DE69733132D1 (de) 2005-06-02
AU724620B2 (en) 2000-09-28
EP0893949B1 (de) 2005-04-27

Similar Documents

Publication Publication Date Title
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DE69523745D1 (de) Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
MD990262A (en) Method of prophylaxis or delay of the Alzheimer disease start and therapeutic product effective for prevention of said disease
DK0920309T3 (da) Konjugeret linolensyre til bevaring eller forøgelse af mineralindhold i knogler
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE303817T1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
EA199700151A1 (ru) Композиция для чрескожного введения
DE69739970D1 (de) Methode zur behandlung sexueller fehlfunktionen
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties